Research dossier

Hexarelin — dossier on the GHS-R1a receptor secretagogue

A hexapeptide derived from GHRP-6, among the most potent of its family — and one of the few to also bind the CD36 receptor.

7 min read · Purpeptide Research Desk ·

Translated from the French original, which remains the reference version: lire en français →

The hexarelin hexapeptide, six amino acids including D-2-methyl-tryptophan, and its two described targets: the GHS-R1a receptor and the CD36 receptor

Hexarelin — international nonproprietary name examorelin — is a hexapeptide of the GHRP (growth hormone-releasing peptides) family. It was designed in the early 1990s as a derivative of GHRP-6, with one objective: to obtain a more marked release of growth hormone.

This dossier describes its identity, its studied mechanisms, the limits of its literature and its analytical parameters. It contains no information on use.

Molecular identity

ParameterValue
CAS number140703-51-1
Molar mass887.04 g/mol
Molecular formulaC₄₇H₅₈N₁₂O₆
Sequence / natureHis-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH₂
Purity≥99%
AppearanceWhite lyophilised powder

The values above are those of the product page and agree with the compound’s PubChem record, listed under its international name, examorelin.

Lineage from GHRP-6

The sequence of hexarelin reproduces that of GHRP-6 with one difference: the D-tryptophan in second position is replaced by a D-2-methyl-tryptophan. That additional methyl group — the only difference between the two formulas — was enough, in the work that characterised it, to produce a greater GH release than its precursor.

Mechanism studied: the GHS-R1a receptor

Like the other GHRPs, hexarelin activates the GHS-R1a receptor, the ghrelin receptor, on the cells of the pituitary and hypothalamus. That activation triggers the release of growth hormone by a pathway distinct from that of GHRH and analogues such as tesamorelin or CJC-1295.

It is not selective for GH. The published studies also describe an elevation of ACTH, cortisol and prolactin — the opposite of Ipamorelin, characterised precisely for its selectivity.

A second target: the CD36 receptor

Hexarelin has a feature rare in its family. Work has shown that it binds the CD36 receptor, a scavenger receptor expressed notably in cardiac tissue. In animal models, that binding has been associated with effects on the heart independent of growth hormone. These observations remain preclinical.

The question of desensitisation

Several studies have described an attenuation of the growth hormone response during prolonged exposure to hexarelin. This desensitisation is an important parameter in any experimental design covering extended durations.

Regulatory status

Hexarelin is not authorised as a medicine in any country. Like all growth hormone secretagogues, it appears in section S2 of the World Anti-Doping Agency prohibited list. See our article on the legal framework for peptides in France.

Distinguishing this compound from its analogues

CritèreHexarelinGHRP-6Ipamorelin
Length6 amino acids6 amino acids5 amino acids
Molecular mass887.04 g/mol873.01 g/mol711.86 g/mol
Selectivity for GHLowLowHigh
CD36 binding describedYes——

Methodological limits

The literature on hexarelin is mainly old, concentrated in the 1990s and 2000s. The work on the CD36 receptor remains preclinical, and desensitisation complicates the interpretation of prolonged exposure studies.

Analytical parameters

With a mass of 887.04 g/mol, hexarelin differs from GHRP-6 (873.01 g/mol) only by a methyl group, a gap of 14 daltons. That gap is easily resolved by mass spectrometry, but it makes it necessary to verify the identity of each lot: a material sold as hexarelin must show the mass of hexarelin, not that of GHRP-6.

Lot verification

The Janoshik certificates of analysis for the catalogue are collected in the lot report register, where each report is tied to the strength and the lot it analyses.

Frequently asked questions

Do hexarelin and examorelin designate the same compound?

Yes. Hexarelin is the common name and examorelin the international nonproprietary name.

What is the difference between hexarelin and GHRP-6?

A methyl group on the tryptophan in second position. That modification produced a more marked GH release in the work that characterised it.

Is hexarelin selective for growth hormone?

No. The studies also describe an elevation of ACTH, cortisol and prolactin. Ipamorelin is the GHRP characterised for its selectivity.

What is the CD36 receptor?

A receptor expressed notably in cardiac tissue, to which hexarelin binds. The associated effects were observed in animal models, independently of growth hormone.

Further reading: CJC-1295, Ipamorelin, GHRP-6: GHRH and GHRP compared · Tesamorelin: the dossier

Dossiers in the same category

References

  • Ghigo E, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab. 1994. PubMed

Related dossiers

All research dossiers → · Catalogue → · Glossary →